SEC Form 4 · accession 0001213900-17-003796
Icagen, Inc. · ICGN
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Vincent Palmieri
Director
Period of report
Jun 30, 2016
Accepted (ET)
Apr 14, 2017 · 4:12 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001518520
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| WarrantF1 | $3.50 | Jun 30, 2016 | A | 6,000 | A | Jun 30, 2016 | Jun 29, 2021 | Common Stock | 6,000 | 6,000 | D |
Explanation of responses
- F1Icagen, Inc. (the "Company") issued Units in a private placement offering (the "Offering") consummated in June 2016 with each Unit consisting of (i) a note in the principal amount of $10,000, and (ii) a five- year warrant to acquire 1,500 shares of Company's common stock, par value, $0.001 per share ("Common Stock"), at an exercise price of $3.50 per share. The Company retained Taglich Brothers, Inc. as the exclusive placement agent (the "Placement Agent") for the Offering. As compensation for the Placement Agent's services in the Offering, the Company (i) paid the Placement Agent a cash commission , and (ii) issued the Placement Agent warrants exercisable for an aggregate amount of 28,625 shares of Common Stock at an exercise price of $3.50 per share. The reporting person received the warrants disclosed herein as the designee of the Placement Agent.